| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2022 ( Subtotal = $154,898 ) |
| | 2022 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R21AI137571 | Serine hydrolase regulators of Mycobacterium tuberculosis non-replicating states | 001 | 1 | NIH | 9/26/2022 | $1 |
| | 2022 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R21DA046168 | Impact of Cigarette Smoke on RNA-cap Modifications within HIV Infected Cells | 000 | 1 | NIH | 9/26/2022 | $1,846 |
| | 2022 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R01DE026336 | Harnessing oral mucosa vaccination to drive protective HIV antibody responses | 000 | 3 | NIH | 9/26/2022 | $6 |
| | 2022 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R01AI134630 | Mediators of fatty liver disease during HIV/SIV and cART treatment | 001 | 1 | NIH | 9/26/2022 | $0 |
| | 2022 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R01AI125706 | Engineering of genetically attenuated pre-erythrocytic Plasmodium parasites for cross-stage protective immunity | 001 | 3 | NIH | 9/26/2022 | $8,159 |
| | 2022 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R03AI137599 | Phosphotyrosine Recognition in Bacteria | 000 | 1 | NIH | 9/26/2022 | $1 |
| | 2022 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R21AI130685 | Protein kinase AEK1 as a T. brucei drug target and its potential in other trypanosomatids | 001 | 1 | NIH | 9/26/2022 | $0 |
| | 2022 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R01AI134956 | Molecular Determinants of Sporozoite / Host Cell Interactions | 000 | 1 | NIH | 9/26/2022 | $1 |
| | 2022 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R01AI117234 | Infection-blocking antibody targets for malaria | 002 | 3 | NIH | 6/29/2022 | -$74 |
| | 2022 | 2018 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R01AI014102 | Mitochondrial DNA of Normal and Mutant Trypanosomes | 001 | 41 | NIH | 9/23/2022 | $15 |
| | 2022 | 2017 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | U19AI106761 | Omics for TB Disease Progression (OTB) | 000 | 5 | NIH | 9/26/2022 | $658 |
| | 2022 | 2017 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R01AI103858 | Base J and transcription termination in Leishmania | 000 | 5 | NIH | 9/26/2022 | $144,285 |
| | 2022 | 2017 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R01AI114766 | Adhesive Interactions in Severe Malaria | 000 | 3 | NIH | 9/23/2022 | $0 |
| | 2022 | 2017 | SEATTLE BIOMEDICAL RESEARCH INSTITUTE | 307 WESTLAKE AVE N STE 500 | SEATTLE | WA | 98109-5240 | KING | USA | R01AI117234 | Infection-blocking antibody targets for malaria | 001 | 2 | NIH | 6/29/2022 | $0 |
|
|
